Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825587 | 0.80 | MAPT (0.45) | LMNAF9HPGD | |
| SCHEMBL7696376 | 0.79 | NR4A2 (0.40) | LMNAKMT2ASRCCYP3A4 | |
| SCHEMBL18691141 | 0.79 | NQO2 (0.39) | LMNASRCCYP3A4 | |
| SCHEMBL6586731 | 0.74 | MAPT (0.46) | LMNAKMT2ACRHR1MEN1CYP3A4 | |
| SCHEMBL19554032 | 0.73 | MAPT (0.42) | LMNAHTTKMT2ACRHR1APP | |
| SCHEMBL7693395 | 0.72 | MEN1 (0.43) | LMNAHTTKMT2AMEN1CYP3A4 | |
| SCHEMBL23015392 | 0.71 | GRM2 (0.33) | CYP3A4 | |
| SCHEMBL14690644 | 0.71 | KDM4E (0.40) | LMNASRCCYP3A4 | |
| SCHEMBL19554036 | 0.71 | MAPT (0.41) | LMNAHTTKMT2ACRHR1ADORA1 | |
| SCHEMBL1577694 | 0.71 | LMNA (0.43) | LMNAHTTKMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3229801-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030036-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | LMNA 1056/4885ADRA2A 2869/4885CLCN2 2346/4885 |
| US-10189819-B2 | Factor IXa inhibitors | F9, TFPI, F12 | LMNA 1056/4885ADRA2A 2869/4885CLCN2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.